+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid in chronic liver disease



Ursodeoxycholic acid in chronic liver disease



Gut 32(9): 1061-1065



The hydrophilic bile acid ursodeoxycholic acid has recently been shown to reduce biochemical markers of both cholestasis and hepatocellular damage in patients with chronic liver diseases. The most compelling evidence available is for chronic cholestatic liver diseases, in particular primary biliary cirrhosis, primary sclerosing cholangitis, and cholestasis associated with cystic fibrosis. The effects may be less beneficial in patients with advanced liver disease from these conditions. Data from placebo controlled trials are now available in support of earlier uncontrolled observations, but it is not yet clear whether short term benefit results in an improvement in longterm prognosis. The mechanism of action of the compound seems to reside in its displacement of toxic hydrophobic bile acids from both the bile acid pool and hepatocellular membranes. There may be an independent effect on bile flow, which could be of particular importance in cystic fibrosis, and possibly an effect on the immune system. Ursodeoxycholic acid should now be regarded as occupying a central place in the medical management of chronic cholestatic liver diseases, in particular primary biliary cirrhosis, because it improves cholestasis and reduces hepatocellular damage and it is not toxic. Research should now be targeted on whether treatment with ursodeoxycholic acid, initiated early in cholestatic liver conditions, improves the long-term outcome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034144837

Download citation: RISBibTeXText

PMID: 1916492

DOI: 10.1136/gut.32.9.1061


Related references

Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy. Journal Of Gastroenterology & Hepatology. 11(4): 385-390, 1996

Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease. Internal Medicine 41(10): 774-779, 2002

Chronic non-cholestatic liver disease and ursodeoxycholic acid treatment Efficacy and evaluation of liver function. European Journal of Clinical Investigation 23(SUPPL 1): A15, 1993

Ursodeoxycholic acid in the treatment of chronic liver disease. American Journal of Gastroenterology 89(9): 1447-1452, 1994

Treatment of chronic liver disease with ursodeoxycholic acid. Journal of International Medical Research 18(6): 497-505, 1990

The rationale for using ursodeoxycholic acid in chronic liver disease. Acta Gastro-Enterologica Belgica 53(4): 402-408, 1990

Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. European Journal of Gastroenterology & Hepatology 7(2): 151-154, 1995

Effect of different doses of ursodeoxycholic acid in chronic liver disease. Digestive Diseases and Sciences 34(12 Suppl): 59s-65s, 1989

Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. Jpma. Journal of the Pakistan Medical Association 56(3): 130-131, 2006

Ursodeoxycholic acid treatment for chronic cholestatic liver disease. Journal of Hepatology 11(1): 5-8, 1990

Sulfation of ursodeoxycholic acid in serum of patients with chronic liver disease. Gastroenterology 104(4 SUPPL ): A961, 1993

Chronic graft-vs.-host disease of the liver: another indication of ursodeoxycholic acid?. Hepatology 16(5): 1305-1307, 1992

Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope. Lakartidningen 99(12): 1325-1330, 2002

Combination therapy of ursodeoxycholic acid and silymarin in non cholestatic chronic liver disease. European Journal of Clinical Investigation 21(2 PART 2): 13, 1991

Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiologica Hungarica 80(1-4): 363-367, 1992